Literature DB >> 8218029

Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases.

P De Potter1, C L Shields, J A Shields, H Menduke.   

Abstract

Sixty eight cases of histologically proved conjunctival melanoma were reviewed in order to determine the clinical factors that were predictive of local recurrence and distant metastasis. All patients were treated with surgical excision and most had supplemental cryotherapy. The mean follow up was 7.5 years. Histopathologically, the conjunctival melanoma arose from primary acquired melanosis in 56%, from naevus in 26%, and de novo in 18%. Of the 68 patients, 38 (56%) developed at least one local tumour recurrence and 22 (32%) developed more than one recurrence. The method of initial treatment and the eventual development of metastasis were the two parameters statistically associated with tumour recurrence. Those patients treated initially with tumour excision alone had a statistically significant higher recurrence rate than those treated initially with excision and supplemental cryotherapy (p = 0.001). Fourteen patients (21%) developed metastasis and the mean period between treatment and metastasis was 3.6 years. Twelve (18%) died from metastatic melanoma with a mean interval of 4.4 years from the time of initial surgery until death. The only clinical parameter that was statistically associated with distant metastasis was local tumour recurrence (p = 0.015). Based on these observations, the authors make recommendations regarding the treatment of conjunctival malignant melanoma. It appears that initial complete excision of the tumour with supplemental cryotherapy offers the patient the best chance of remaining free of recurrence and metastasis.

Entities:  

Mesh:

Year:  1993        PMID: 8218029      PMCID: PMC504602          DOI: 10.1136/bjo.77.10.624

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  21 in total

1.  The role of cryotherapy in the management of conjunctival melanoma.

Authors:  F A Jakobiec; S Brownstein; W Albert; F Schwarz; R Anderson
Journal:  Ophthalmology       Date:  1982-05       Impact factor: 12.079

2.  Conjunctival melanosis and melanoma.

Authors:  R Folberg; I W McLean; L E Zimmerman
Journal:  Ophthalmology       Date:  1984-06       Impact factor: 12.079

3.  Cryotherapy for precancerous melanosis (atypical melanocytic hyperplasia) of the conjunctiva.

Authors:  S Brownstein; F A Jakobiec; R D Wilkinson; J Lombardo; W B Jackson
Journal:  Arch Ophthalmol       Date:  1981-07

4.  Malignant melanoma of the conjunctiva.

Authors:  R Folberg; I W McLean; L E Zimmerman
Journal:  Hum Pathol       Date:  1985-02       Impact factor: 3.466

5.  [Melanoma of the conjunctiva and its treatment].

Authors:  L Zografos; S Uffer; C Gailloud; L Bercher
Journal:  Klin Monbl Augenheilkd       Date:  1990-05       Impact factor: 0.700

6.  Cryotherapy for intraepithelial conjunctival melanocytic proliferations. Ultrastructural effects.

Authors:  F A Jakobiec; T Iwamoto
Journal:  Arch Ophthalmol       Date:  1983-06

7.  Conjunctival melanocytic lesions in children.

Authors:  J M McDonnell; J D Carpenter; P Jacobs; W L Wan; J E Gilmore
Journal:  Ophthalmology       Date:  1989-07       Impact factor: 12.079

8.  Cryotherapy for conjunctival primary acquired melanosis and malignant melanoma. Experience with 62 cases.

Authors:  F A Jakobiec; F J Rini; F T Fraunfelder; S Brownstein
Journal:  Ophthalmology       Date:  1988-08       Impact factor: 12.079

Review 9.  Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva.

Authors:  F A Jakobiec; R Folberg; T Iwamoto
Journal:  Ophthalmology       Date:  1989-02       Impact factor: 12.079

Review 10.  The ultrastructure of conjunctival melanocytic tumors.

Authors:  F A Jakobiec
Journal:  Trans Am Ophthalmol Soc       Date:  1984
View more
  23 in total

1.  Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma.

Authors:  S Seregard
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

Review 2.  [Operative therapy and irradiation of conjunctival melanoma].

Authors:  H Westekemper; D Meller; R Darawsha; S L Scholz; D Flühs; K-P Steuhl; J Hérault; J Thariat; W Sauerwein
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

Review 3.  Conjunctival melanoma in Southwestern Nigeria: a case series and review of literature.

Authors:  Oluyemi Fasina; Olayiwola A Oluwasola
Journal:  Int Ophthalmol       Date:  2017-06-19       Impact factor: 2.031

Review 4.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

5.  Expression of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of MMP (TIMP)-1 in conjunctival melanomas and clinical implications.

Authors:  Hyoung Kyun Kim; Seoung Wan Chae; Kyung In Woo; Yoon-Duck Kim
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

6.  Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population.

Authors:  J C Norregaard; N Gerner; O A Jensen; J U Prause
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-09       Impact factor: 3.117

7.  Conjunctival melanoma.

Authors:  A B Tullo; R Bonshek
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

8.  Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia.

Authors:  P T Finger; G Czechonska; S Liarikos
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

Review 9.  Conjunctival melanoma and melanocytic intra-epithelial neoplasia.

Authors:  N Kenawy; S L Lake; S E Coupland; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

10.  [Interferon alpha 2b for treatment of conjunctival melanoma: a case report].

Authors:  C Schumacher; C Heinz; P Lommatzsch; A Lommatzsch; J Koch
Journal:  Ophthalmologe       Date:  2013-08       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.